IMGN - イミュノジェン （ImmunoGen Inc.） イミュノジェンIMGNのチャート
IMGNの企業情報
| symbol | IMGN |
|---|---|
| 会社名 | ImmunoGen Inc. （イミュノジェン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 イミュノジェン(ImmunoGen Inc.)は抗体-薬物コンジュゲート（ADC）技術を使用して標的がん治療薬を開発する臨床段階のバイオテクノロジー会社である。同社の技術を用いたADCは、ADCがその標的に結合した後に腫瘍細胞を死滅させるペイロードとしてその抗癌剤の1つに結合した腫瘍細胞上に見出される標的に結合する抗体を含む。その製品候補には、Mirvetuximab soravtansine、IMGN779、IMGN632、及びColtuximab ravtansineが含まれる。同社のポートフォリオは、FORWARD Iと呼ばれるフェーズⅢ登録試験中の葉酸受容体アルファ（Fra）を標的とした初のADCであり、Mirvetuximab soravtansineによって導かれている。FORWARD II試験は、アバスチン（ベバシズマブ）、Keytruda（ペンブロリズマブ）およびカルボプラチンと組み合わせて、ミルベキシマブソラバタンシンを評価するコホートからなる。同社は、DM1およびDM4、並びにIGNと呼ばれるデオキシリボ核酸（DNA）アルキル化剤を含むチューブリン作用性メイタンシノイドペイロード剤を開発した。 イミュノジェンは、米国のバイオ医薬品会社。がんに対する標的治療剤の開発、製造、販売を行う。同社の抗体薬物複合体(ADC)技術は、同社の細胞死滅性化合物を特異的にがん細胞に到達させるため、がん細胞を標的とする抗体を用いている。また、それ自体抗がん活性を有する抗体も同社で開発する。本社は、マサチュ―セッツ州ウォルサム。 ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, the company aims to disrupt the progression of cancer and offer its patients more good days. |
| 本社所在地 | 830 Winter Street Waltham MA 02451 USA |
| 代表者氏名 | Stephen C. McCluski Stephen C. McCluski |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 781-895-0600 |
| 設立年月日 | 29646 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1989年 |
| 従業員数 | 293人 |
| url | www.immunogen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/imgn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -105.55200 |
| 終値（lastsale） | 8.2 |
| 時価総額（marketcap） | 1221974848.6 |
| 時価総額 | 時価総額（百万ドル） 1107.228 |
| 売上高 | 売上高（百万ドル） 77.03000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 764.22700 |
| 当期純利益 | 当期純利益（百万ドル） -150.03700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ImmunoGen Inc. revenues decreased 57% to $29.1M. Net loss increased from $26.2M to $80.2M. Revenues reflect License and milestone fees decrease of 74% to $12.9M Research and development support decrease of 68% to $771K Clinical materials revenue decrease of 19% to $1M. Higher net loss reflects Preclinical and Clinical Testing increase of 50% to $46.9M (expense). |
IMGNのテクニカル分析
IMGNのニュース
Immunogen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial 2023/03/27 09:52:11 Investing.com
https://www.investing.com/news/assorted/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-432SI-3040566
Tiling stocks: ImmunoGen, Inc. (NASDAQ:IMGN 1.25%), MasterBrand, Inc. (NYSE:MBC -2.04%) 2023/03/10 10:15:48 Stock Equity
IMGN has seen its SMA50 which is now -8.94%. In looking the SMA 200 we see that the stock has seen a -17.64%. MBC has seen its SMA50 which is … The post Tiling stocks: ImmunoGen, Inc. (NASDAQ:IMGN 1.25%), MasterBrand, Inc. (NYSE:MBC -2.04%) appeared first on Stocks Equity .
An In-Depth Look At The ImmunoGen Inc. (IMGN) Stock 2023/03/08 14:30:00 Marketing Sentinel
ImmunoGen Inc. (NASDAQ:IMGN) has a beta value of 0.93 and has seen 2.94 million shares traded in the last trading session. The company, currently valued at $944.08M, closed the last trade at $4.20 per share which meant it gained $0.03 on the day or 0.72% during that session. The IMGN stock price is -57.86% off … An In-Depth Look At The ImmunoGen Inc. (IMGN) Stock Read More »
Outrageous stocks: ImmunoGen, Inc. (NASDAQ:IMGN), WeWork Inc. (NYSE:WE) 2023/03/03 08:46:41 Stock Equity
IMGN has seen its SMA50 which is now -1.10%. In looking the SMA 200 we see that the stock has seen a -9.27%. WE has seen its SMA50 which is … The post Outrageous stocks: ImmunoGen, Inc. (NASDAQ:IMGN), WeWork Inc. (NYSE:WE) appeared first on Stocks Equity .
ImmunoGen Inc (IMGN) Q4 2022 Earnings Call Transcript | AlphaStreet 2023/03/02 06:34:41 AlphaStreet
ImmunoGen Inc (NASDAQ:IMGN) Q4 2022 Earnings Call dated Mar. 01, 2023.
Mirati Plays Catch-Up With Amgen, Gilead''s 2nd Try With AIDS Drug, Cytokinetics'' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors 2022/12/02 11:01:03 Benzinga
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. The two NMEs that were okayed in November include Provention Bio, Inc.’s (NASDAQ: PRVB ) Tzield, approved for delaying the onset of stage-3, type-1 diabetes, and ImmunoGen Inc.’s (NASDAQ: IMGN ) mirvetuximab soravtansine monotherapy – a treatment for recurrent ovarian cancer resistant to platinum therapy. On the flip side, Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ) received a complete response letter for its lung cancer drug application , prompting the company to pull the plug on the program. The iShares Biotechnology ETF (NASDAQ: IBB ), an exchange-traded fund tracking mostly large-cap biotechs, is down about 10% year-to-date, reflecting the travails faced by the sector. Benzinga has previewed December’s Prescription Drug User Fee Act dates — deadlines fixed by the FDA to communicate its decision about the approval or non-approval of a drug.
ImmunoGen Needs To Make The Most Of Its First-Mover Opportunity (NASDAQ:IMGN) 2022/11/30 12:00:00 Seeking Alpha
ImmunoGen''s Elahere recently received accelerated approval in FRα-high, platinum-resistant ovarian cancer and sports first-mover advantage. Read why IMGN is a Buy.
ImmunoGen Inc.’s (NASDAQ: IMGN) Stock Could Appreciate By -325.53% 2022/11/28 20:00:00 Marketing Sentinel
In the latest trading session, 1.17 million ImmunoGen Inc. (NASDAQ:IMGN) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $5.17 changing hands around $0.02 or 0.39% at last look, the market valuation stands at $1.17B. IMGN’s current price is a discount, trading about -50.29% off its … ImmunoGen Inc.’s (NASDAQ: IMGN) Stock Could Appreciate By -325.53% Read More »
Looking Into Immunogen''s Return On Capital Employed 2022/11/28 14:49:16 Benzinga
Immunogen (NASDAQ: IMGN ) brought in sales totaling $15.38 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 25.37%, resulting in a loss of $77.75 million. In Q2, Immunogen brought in $14.16 million in sales but lost $62.02 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and … Full story available on Benzinga.com
ImmunoGen (IMGN) Stock: Ramifications Of Elahere Approval 2022/11/24 08:15:15 Seeking Alpha
ImmunoGen recently gained the accelerated approval of Elahere for resistant ovarian cancers with high FRA expression. See why I''ve downgraded IMGN stock to a Buy.
ImmunoGen Inc.’s (NASDAQ:IMGN) Stock Is Down -5.39%, But Is It Capable Of A Rally? 2022/11/02 13:00:00 Stocks Register
ImmunoGen Inc. (NASDAQ:IMGN) traded at $5.62 at close of the session on Tuesday, 11/01/22, made a downward move of -5.39% on its previous day’s price. Looking at the stock we see that its previous close was $5.94 and the beta (5Y monthly) reads 0.98 with the day’s price range being $5.33 – $5.99. In terms … ImmunoGen Inc.’s (NASDAQ:IMGN) Stock Is Down -5.39%, But Is It Capable Of A Rally? Read More »
ImmunoGen Announces Departure of Chief Commercial Officer 2022/11/01 10:30:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Departure of Chief Commercial Officer
ImmunoGen Before The PDUFA (NASDAQ:IMGN) 2022/10/27 11:00:24 Seeking Alpha
ImmunoGen has a critical PDUFA date next month, based on more or less strong data in a patient population with high unmet need. Read why IMGN is a Hold.
Can you now get a good deal on ImmunoGen Inc.’s shares? 2022/10/26 13:48:00 US Post News
In Tuesday’s session, ImmunoGen Inc. (NASDAQ:IMGN) marked $6.05 per share, up from $6.00 in the previous session. While ImmunoGen Inc. has overperformed by 0.83%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMGN rose by 3.24%, with highs and lows ranging from $7.77 to $3.10, whereas […]
At What Point In Time Would I Choose To Purchase ImmunoGen Inc. (NASDAQ: IMGN) Stock? 2022/10/25 11:00:00 Stocks Register
The trading price of ImmunoGen Inc. (NASDAQ:IMGN) closed lower on Monday, October 24, closing at $6.00, -2.28% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $5.945 and $6.245. In examining the 52-week price action we see that the stock hit a 52-week high … At What Point In Time Would I Choose To Purchase ImmunoGen Inc. (NASDAQ: IMGN) Stock? Read More »